Replies to post #438 on Fate Therapeutics Inc (FATE)

[jondoeuk]

Its an alpha beta CD8+ T-cell product.

Type I NKTs have an invariant TCR and the Rezvani Lab (at MD Anderson) is working on an NK product with that (as well a CD16a receptor and CD3 fusion receptor).

The iTCR can directly recognise and kill CD1d-expressing cancer cells https://www.sciencedirect.com/science/article/abs/pii/S1521661613001757

Also, kill certain immunosuppressive cells in the TME https://www.jci.org/articles/view/37869